Ipamorelin Reconstitution Calculator
A selective growth hormone secretagogue (GHRP class) designed for GH release without significant cortisol, prolactin, or ACTH elevation.
Informational only. Not medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any protocol.
Ipamorelin
About Ipamorelin
Not FDA-approved. Sold as a research chemical. Regulatory status varies by jurisdiction. Users are responsible for legal compliance.
Ipamorelin is a synthetic pentapeptide in the GHRP (growth hormone releasing peptide) class, first described in a 1998 Novo Nordisk research publication. What distinguishes ipamorelin from other GHRPs (GHRP-2, GHRP-6) is its **selectivity** — preclinical studies showed GH release without significant elevation of cortisol, prolactin, or ACTH, which has made it a commonly-studied secretagogue in research contexts.
Half-life is approximately 2 hours. Users tracking ipamorelin in this app commonly log 200–300 mcg per injection, subcutaneously, 2–3 times daily on an empty stomach — typically upon waking and before bed (and sometimes mid-day). Ipamorelin is frequently paired with CJC-1295 (no DAC), which is a GHRH analog — the combination produces synergistic GH release. Ipamorelin is NOT FDA-approved and is classified as a research chemical.
Frequently asked questions
- Why is ipamorelin dosed multiple times daily?
- With a 2-hour half-life, the compound clears quickly from serum. Users tracking a pulsatile GH-axis protocol log 2–3 doses per day to approximate a more natural GH secretion rhythm. The "GH Pulse" stack template captures this pattern.
- Why is ipamorelin paired with CJC-1295 (no DAC)?
- Ipamorelin is a GHRP (works through ghrelin receptor to stimulate GH release). CJC-1295 (no DAC) is a GHRH analog (works through the GHRH receptor). The two mechanisms are complementary — paired dosing produces synergistic GH release in preclinical studies.
- Does ipamorelin raise cortisol?
- In early preclinical studies, ipamorelin was specifically selected for its lack of cortisol, prolactin, and ACTH elevation — a distinguishing feature from older GHRPs like GHRP-2 and GHRP-6. This is why ipamorelin is often preferred for research protocols requiring GH-axis isolation.
Sources
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998. PMID: 9849822
- Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sex Med Rev. 2018. PMID: 28483625
The app runs every compound.
This page runs one. My Pep Calc runs your whole stack — reconstitution math feeds your dose log, which feeds your site rotation map and the half-life chart. First 500 founders get Lifetime Pro for $149.
See the Founders offer →